2017 The new Capital, page-469

Hi all,
The following is a copy of the email I sent to Capitol in late June. I've just sent it again (4th time). Not difficult questions I would have thought and I doubt they are market sensitive either. Not holding my breath waiting for a response.


Hello Andrew,

Firstly, belated congratulations on your appointment to Managing Director and on behalf of all shareholders, thank you for the stunning turnaround in the company since taking that position. I've been investing in Capitol Health for over 2 years and from an original small holding I now hold X shares.
If you could indulge me I have a couple of questions regarding the use of Enlitic in Australia.

I recently watched a You Tube video of Kevin Lyman's Enlitic presentation at the Cube Tech Fair. In the Q&A he stated that their patient triage tool is being trialled in Australia but not their CT lung scan as it does not have regulatory approval here.

> Have we applied for approval yet and if so what is the expected time frame for gaining approval?

In late June (19/6/17) I saw several news reports on a new lung cancer screening trial to be carried out at the Royal Melbourne Hospital. The aim of the trial is to improve early detection in at risk patients and also determine if there is any merit to a national screening program. In one report, the argument against a national program was the high number of false positives that can arise from CT scans. Surely this is a golden opportunity for the company to demonstrate the potential of Enlitic and may also be a stepping stone to gaining regulatory approval.

> Is Capitol Health participating in the RMH lung cancer trials (or planning to)?
>If we are not to participate, why not?

Thanks in advance.

Yours sincerely,


Ps. I am a member of HotCopper. With your permission would like to share your answers with other Capitol Health share holders on that forum.